PulseMedica Raises $12 Million to Advance Eye Floater Imaging and Treatment Technology

PulseMedica announced that it has raised an aggregate of $12 million to date in investment as part of their pre-Series A financing round. This investment allowed PulseMedica to generate initial results from their preclinical and clinical studies, and will continue to accelerate the clinical validation of PulseMedica’s floater imaging device. Additionally, the investment supports ongoing laser safety and feasibility studies needed for the first-in-human clinical trial for floater treatment. Funds are also directed toward expanding the technical and business teams in preparation for commercialization and regulatory approvals, according to a company news release.

Saltagen Ventures led the financing round with participation from Accelerate Fund III, ScaleGood Fund, ThresholdImpact, UCeed Health Fund, Startup TNT and the University of Alberta’s Innovation Fund.

Receiving the support underscores PulseMedica's efforts in developing what the company calls first effective diagnostic and treatment devices for eye floaters. 

“Eye disease impacts hundreds of millions world-wide. PulseMedica’s team is dedicated to improving the quality of life for millions experiencing visual disorders with unique diagnostics and treatments. We are excited to finally share this news with the world," Co-Founder and CEO of PulseMedica, Dr. Nir Katchinskiy, said in the news release. "The timing of this announcement and coming out of ‘stealth-mode’ is triggered by initial exciting results from our preclinical and clinical studies on imaging and treatment of eye floaters. The financing will continue to help provide us with the ability to advance our platform and further validate its performance in a clinical setting. With this success, we are preparing for the opening of a Series A fundraising round which will support future clinical studies essential for regulatory approvals. We are grateful for the support from our new investors and existing shareholders and the dedication from startup enablers like Creative Destruction Lab, Alberta Innovates, INOVAIT, and NRC IRAP.”

Since 2020, PulseMedica has raised over $16 million, including a $6.5 million investment from a multinational strategic in 2023. Recent funding has enabled substantial progress in research and development, resulting in the development of 7 prototype devices and the filing of 14 patents.

For investor inquiries about the current or future fundraising rounds, email investors@pulsemedica.com.